Conexiant
Login
  • The Analytical Scientist
  • The Cannabis Scientist
  • The Medicine Maker
  • The Ophthalmologist
  • The Pathologist
  • The Traditional Scientist
The Medicine Maker
  • Explore

    Explore

    • Latest
    • Features
    • Interviews
    • Business & Trends
    • Technology & Manufacturing
    • Product Profiles
    • White Papers

    Featured Topics

    • Biopharma
    • Small Molecules
    • Cell & Gene
    • Future of Pharma

    Issues

    • Latest Issue
    • Archive
    • Cell and Gene Therapy Supplement
  • Topics

    Topics

    • Drug Discovery
    • Development & Clinical
    • Formulation
    • Drug Delivery
    • Bioprocessing
    • Small Molecules
    • Cell and Gene
    • Facilities & Equipment
    • Outsourcing
    • Packaging
    • Supply Chain
    • Regulation & Standards
  • News & Blogs

    News & Blogs

    • Industry News
    • Research News
    • Blogs
  • Events
    • Live Events
    • Webinars
  • Community & Awards

    Community & Awards

    • Power List
    • Sitting Down With
    • Innovation Awards
    • Company of the Year Awards
    • Authors & Contributors
  • Multimedia
    • Video
    • Podcasts
    • eBooks
Subscribe
Subscribe
The Medicine Maker / Issues / 2024 / Articles / Nov / The Role of AI in Market Launch
Business & Regulation Technology and Equipment Business Practice Digital Technologies Marketing Technology & Manufacturing Business & Trends

The Role of AI in Market Launch

How AI can help foster marketing-sales collaboration.

By Philip Poulidis 11/29/2024 5 min read

Share

Successful commercial execution in the biopharma industry can transform patients’ lives. The process from identifying healthcare professionals (HCPs) to educating them about treatment options requires real-time, connected coordination across marketing and sales teams for maximum effect. Despite digital transformation efforts accelerating, many companies still struggle with disconnected teams and processes. A digital divide exists between brand strategy and sales execution. Biopharma companies fail to coordinate their digital engagement for nearly three out of four doctors The result: missed opportunities with physicians and limited commercial impact.

Well-executed AI initiatives can bridge the digital divide and help biopharma shift from static strategies to dynamic, data-driven commercial models. Marketing and sales teams can then quickly adapt to changing business requirements, seamlessly connect strategy to execution, and take a data-driven, predictive approach to meeting doctor and patient needs.

Traditional HCP targeting is decades-old and slow, using decile-based analysis to identify and prioritize physicians. External consultants typically spend months reviewing backward-looking prescription data. By the time sales gets their target lists from marketing, the information is stale because of the time lag and manual effort involved. When market conditions change, an entirely new analysis must be done, taking even more time.

If AI is used in commercial operations today, it’s a black box and largely remains a consultant’s playground. Now, off-the-shelf, scalable AI solutions can automate in near real-time what takes consultants months. It can evaluate hundreds of thousands of physicians and millions of de-identified longitudinal patient records across many regions to determine the best doctors to target, understand their prescribing behavior, and determine what outcomes were for patients.

The best part? An AI-powered approach delivers real-time insights for marketing to make immediate adjustments. Teams can quickly pivot in response to market shifts, competitive changes, and evolving brand objectives.

Commercial teams have accumulated numerous tools such as CRM, business intelligence, sales planning and forecasting, virtual engagement, and content management tools to enhance field performance. Sales teams use an average of 10 tools, but this fragmented approach makes it hard to gather and deliver insights to the field in a simple, user-friendly way. Understandably, when it comes to AI, biopharma is hesitant to introduce yet another tool. To further bridge the gap between brand strategy and field operations, AI must integrate into the ways sales reps are already working. For example, companies can leverage their existing data, run AI, and deliver intelligence to CRM, which is at the center of every sales rep’s workflow, without significant change management or disrupting their current tools. AI-driven insights can be seamlessly blended into sales reps’ routines as they prepare for their week, day, or individual calls with HCPs.

Marketing and sales play critical roles in keeping physicians informed about possible treatments for their patients. The pace of innovative new medicines and therapies make it hard for doctors to stay up to date. Data shows that when digital-savvy doctors get the scientific information they need, they’re more likely to adopt new treatment options.

This is why biopharma companies should invest heavily in their field force. While AI is revolutionizing drug discovery and clinical trials, it remains largely untapped in commercial operations. There is a significant opportunity for AI to replace old ways of working, automate them, and make them much faster and much more efficient. The future of patient care hinges on closing the digital gap between marketing and sales. Every biopharma marketer and sales rep shares a common mission to accelerate time to therapy for patients everywhere.

A more efficient and data-driven process closes gaps in care and enhances healthcare delivery. In the long run, AI can help drive more efficient healthcare systems, enable HCPs to better serve their patients, and contribute to the broader mission of making healthcare more accessible and effective for everyone.

Philip Poulidis

Newsletters

Receive the latest analytical science news, personalities, education, and career development – weekly to your inbox.

Newsletter Signup Image

About the Author(s)

Philip Poulidis

Philip Poulidis, CEO and co-founder, ODAIA

More Articles by Philip Poulidis

False

Advertisement

Recommended

False

Related Content

Battle of the Superbugs
Drug Discovery Technology and Equipment
Battle of the Superbugs

December 1, 2014

0 min read

Can phage endolysins revolutionize the way bacterial infections are treated – and prevent drug resistance?

All a Big Game?
Business Practice Technology and Equipment Trends & Forecasts
All a Big Game?

November 6, 2014

0 min read

“Welcome to Big Pharma, where you can make a fortune and still maintain a healthy conscience. Or can you?”

Beware the Dragonfly
Business Practice Technology and Equipment Trends & Forecasts
Beware the Dragonfly

November 6, 2014

0 min read

Mysterious cyber attackers are hitting pharma manufacturing systems

Future Proofing Track and Trace
Standards & Regulation Technology and Equipment
Future Proofing Track and Trace

November 6, 2014

0 min read

The US is finally introducing regulation on drug serialization and traceability, but gaps remain that could leave patients vulnerable.

The Medicine Maker
Subscribe

About

  • About Us
  • Work at Conexiant Europe
  • Terms and Conditions
  • Privacy Policy
  • Advertise With Us
  • Contact Us

Copyright © 2025 Texere Publishing Limited (trading as Conexiant), with registered number 08113419 whose registered office is at Booths No. 1, Booths Park, Chelford Road, Knutsford, England, WA16 8GS.